PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Gilead gets FDA nod for multi-drug resistant HIV treatment

The U.S. FDA has approved Gilead’s Sunlenca (lenacapavir), a new type of antiretroviral medication for adult patients whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance or safety considerations.

Sunlenca is the first of a new class of drugs called capsid inhibitors to be FDA-approved for treating HIV-1. Sunlenca works by blocking the HIV virus’ protein shell (the capsid), thereby interfering with multiple essential steps of the viral life cycle.  The drug’s starting dose is given as oral tablets and subcutaneous injections, followed by maintenance injections every six months; Sunlenca is given in combination with other antiretrovirals.

The FDA had rejected Gilead’s NDA for Sunlenca back in March. In the complete response letter, the FDA said its decision to reject the candidate was due to CMC issues with the glass vials the drug was intended to be distributed in. Specifically, the agency raised questions about vials made of borosilicate glass and their compatibility with lenacapavir solution. The European Commission approved the drug a few months later in August. 

The FDA approval for Sunlenca is supported by data from the phase 2/3 CAPELLA trial, which evaluated lenacapavir in combination with an optimized background regimen in people with multi-drug resistant HIV-1 who are heavily treatment-experienced. CAPELLA participants had undergone previous treatment with a median of nine antiretroviral medications. According to Gilead, in this patient population with a significant unmet medical needs, 83% of participants randomly allocated to receive lenacapavir in addition to an optimized background regimen achieved an undetectable viral load at week 52.

Despite the significant advances in ARV therapy, there remain numerous critical and pressing unmet needs for people living with HIV. This is particularly true for individuals who are heavily treatment-experienced and are unable to maintain virologic suppression.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026